Amgen Inc. $AMGN Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 3.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 401,226 shares of the medical research company’s stock after selling 14,784 shares during the quarter. Janney Montgomery Scott LLC owned about 0.07% of Amgen worth $145,292,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. North Dakota State Investment Board grew its position in Amgen by 0.3% in the second quarter. North Dakota State Investment Board now owns 15,994 shares of the medical research company’s stock valued at $5,792,000 after acquiring an additional 50 shares in the last quarter. USA Financial Formulas acquired a new position in shares of Amgen during the first quarter worth $655,000. Aviso Wealth Management boosted its stake in shares of Amgen by 3.1% in the second quarter. Aviso Wealth Management now owns 2,681 shares of the medical research company’s stock valued at $971,000 after purchasing an additional 80 shares during the period. Investment Research Partners LLC boosted its stake in shares of Amgen by 6.1% in the second quarter. Investment Research Partners LLC now owns 3,890 shares of the medical research company’s stock valued at $1,409,000 after purchasing an additional 224 shares during the period. Finally, 71 West Capital Partners grew its holdings in Amgen by 58.8% during the 2nd quarter. 71 West Capital Partners now owns 3,626 shares of the medical research company’s stock valued at $1,313,000 after purchasing an additional 1,343 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 6,222 shares of company stock worth $2,540,926 in the last 90 days. 0.85% of the stock is currently owned by insiders.

Amgen Price Performance

Shares of AMGN stock opened at $415.21 on Monday. The firm has a fifty day moving average of $370.57 and a two-hundred day moving average of $358.99. The firm has a market cap of $224.48 billion, a P/E ratio of 25.81, a P/E/G ratio of 3.86 and a beta of 0.41. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $421.79. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same quarter in the prior year, the business posted $6.02 EPS. The company’s revenue for the quarter was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, research analysts anticipate that Amgen Inc. will post 22.78 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.4%. Amgen’s dividend payout ratio is presently 62.65%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Royal Bank Of Canada lifted their price target on shares of Amgen from $370.00 to $400.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Oppenheimer upped their price objective on shares of Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Cantor Fitzgerald restated a “neutral” rating and set a $350.00 target price on shares of Amgen in a research note on Monday, July 6th. Bank of America lifted their target price on Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th. Finally, Wells Fargo & Company boosted their price target on Amgen from $390.00 to $400.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $372.39.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.